{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:35:17Z","timestamp":1791992117271,"version":"4.4.0"},"reference-count":35,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT 2025222"],"award-info":[{"award-number":["GNT 2025222"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2024,9,29]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Non-infectious uveitis is a diverse group of inflammatory conditions that collectively account for substantial blindness worldwide. Expert guidelines and results of clinical trials guide treatment, but real-world clinical care is impacted by additional factors. In 2023, an international group of uveitis-specialised ophthalmologists formed the\n                      <jats:italic>International Study Group for Systemic Immunomodulatory Drug Treatment of Non-Infectious Uveitis<\/jats:italic>\n                      to report current practice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>221 study group members from 53 countries completed a 30-item questionnaire on their management of non-infectious uveitis including: indications for and investigations prior to initiating systemic immunomodulatory drugs, use of conventional and biological drugs, and follow-up of treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Major indications to initiate systemic immunomodulatory drugs were: uveitis not controlled with oral prednis(ol)one (n=208, 94.1%), specific uveitis diagnosis (n=197, 89.1%), and patient intolerance of oral prednis(ol)one (n=186, 84.2%). All members (n=221, 100%) performed pretreatment screens including: blood chemistry (n=217, 98.2%), blood examination (n=207, 93.7%), and Quantiferon assay (n=196, 88.7%). Eight conventional and 14 biological drugs were prescribed: methotrexate was the preferred conventional drug overall (n=126, 57.0%) and for 9 of 11 uveitides, and adalimumab was the preferred biological drug overall (n=216, 97.7%) and for 11 of 11 uveitides. When drugs were combined, methotrexate plus adalimumab was most popular (n=158 of 188 members, 84.0%). Patients with inactive uveitis were typically evaluated and screened for drug toxicity every 6\u201312 weeks (n=161, 72.9%, and 165, 74.7%, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our report describes practice patterns of a large international group of uveitis specialists treating non-infectious uveitis with systemic immunomodulatory drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2024-326239","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T13:20:25Z","timestamp":1730208025000},"page":"482-489","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice"],"prefix":"10.1136","volume":"109","author":[{"given":"Jasmin A","family":"Branford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisia Barros","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"McCluskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet M","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International Study Group for Systemic Immunomodulatory Drug Treatment of Non\u2010Infectious Uveitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-5493","authenticated-orcid":false,"given":"Justine R","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"2025032402050719000_109.4.482.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2011.06.005"},{"key":"2025032402050719000_109.4.482.2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.037226"},{"key":"2025032402050719000_109.4.482.3","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1746352"},{"key":"2025032402050719000_109.4.482.4","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1687733"},{"key":"2025032402050719000_109.4.482.5","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2201324"},{"key":"2025032402050719000_109.4.482.6","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1828493"},{"key":"2025032402050719000_109.4.482.7","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12987"},{"key":"2025032402050719000_109.4.482.8","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2247077"},{"key":"2025032402050719000_109.4.482.9","first-page":"509","article-title":"Standardization of uveitis nomenclature for reporting clinical data","volume":"140","author":"Jabs","year":"2005","journal-title":"Results First Int Workshop Am J Ophthalmol"},{"key":"2025032402050719000_109.4.482.10","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14175"},{"key":"2025032402050719000_109.4.482.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.04.020"},{"key":"2025032402050719000_109.4.482.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.05.008"},{"key":"2025032402050719000_109.4.482.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.09.026"},{"key":"2025032402050719000_109.4.482.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.08.010"},{"key":"2025032402050719000_109.4.482.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852"},{"key":"2025032402050719000_109.4.482.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31339-3"},{"key":"2025032402050719000_109.4.482.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.12.039"},{"key":"2025032402050719000_109.4.482.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.07.001"},{"key":"2025032402050719000_109.4.482.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.01.003"},{"key":"2025032402050719000_109.4.482.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.11.017"},{"key":"2025032402050719000_109.4.482.21","first-page":"565","article-title":"Clinical experiences with ACTH and cortisone in ocular diseases","volume":"55","author":"McLean","year":"1951","journal-title":"Trans Am Acad Ophthalmol Otolaryngol"},{"key":"2025032402050719000_109.4.482.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00659-0"},{"key":"2025032402050719000_109.4.482.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221957"},{"key":"2025032402050719000_109.4.482.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12618"},{"key":"2025032402050719000_109.4.482.25","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.097998"},{"key":"2025032402050719000_109.4.482.26","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000371"},{"key":"2025032402050719000_109.4.482.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614160"},{"key":"2025032402050719000_109.4.482.28","unstructured":"Abbvie . AbbVie\u2019s humira (adalimumab) receives U.S. food and drug administration approval to treat adults with non-infectious intermediate, posterior and panuveitis. 2016. Available: https:\/\/news.abbvie.com\/2016-06-30-AbbVies-HUMIRA-adalimumab-Receives-U-S-Food-and-Drug-Administration-Approval-to-Treat-Adults-with-Non-Infectious-Intermediate-Posterior-and-Panuveitis?_ga=2.10814967.292436695.1704689841-290722756.1704689841"},{"key":"2025032402050719000_109.4.482.29","unstructured":"Food and Drug Administration . HUMIRA (adalimumab) injection, for subcutaneous use. 2017. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125057s399lbl.pdf"},{"key":"2025032402050719000_109.4.482.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.007"},{"key":"2025032402050719000_109.4.482.31","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2022-322236"},{"key":"2025032402050719000_109.4.482.32","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15308"},{"key":"2025032402050719000_109.4.482.33","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13369"},{"key":"2025032402050719000_109.4.482.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.02.029"},{"key":"2025032402050719000_109.4.482.35","unstructured":"World Health Organization . Web Annex A. World Health Organization model list of essential medicines \u2013 23rd list, 2023. in: the selection and use of essential medicines 2023: executive summary of the report of the 24th WHO expert committee on the selection and use of essential medicines, 24-28 April 2023. licence: CC BY-NC-SA 3.0 IGO. Geneva World Health Organization; 2023."}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2024-326239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T05:16:54Z","timestamp":1742793414000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2024-326239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,3,20]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bjo-2024-326239"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2024-326239","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}